Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | PNMT | P11086 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27654170 | 0.90 | AR (0.52) | ARHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL30738393 | 0.90 | AR (0.52) | ARHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL6754125 | 0.80 | AR (0.46) | ARHTR2AHTR2CHTR2BMTNR1A | |
| SCHEMBL6754129 | 0.80 | AR (0.46) | ARHTR2AHTR2CHTR2BMTNR1A | |
| SCHEMBL6754126 | 0.80 | AR (0.46) | ARHTR2AHTR2CHTR2BMTNR1A | |
| Ethoxycarbonyl Group SCHEMBL29291835 | 0.79 | AR (0.46) | ARMTNR1A | |
| SCHEMBL5790945 | 0.76 | MEN1 (0.41) | ARHTR2AHTR2CHTR2B | |
| SCHEMBL22297852 | 0.76 | AR (0.44) | ARPNMTMTNR1A | |
| SCHEMBL5790950 | 0.76 | MEN1 (0.41) | ARHTR2AHTR2CHTR2B | |
| SCHEMBL6752929 | 0.75 | AR (0.40) | ARHTR2AHTR2CHTR2BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188307-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL COPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | AADAT, KMO, ALDH7A1 | AR 1547/4885HTR2A 1845/4885HTR2C 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.